Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07417943 · ClinicalTrials.gov registry record · NA
Neuromodulation to Enhance Motor Function in HSP
A NA study of Hereditary Spastic Paraplegia, sponsored by Rahul Sachdeva.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07417943: Recruiting NA study of Hereditary Spastic Paraplegia, sponsored by Rahul Sachdeva.
NCT07417943 is a NA study of Hereditary Spastic Paraplegia that is actively recruiting participants, run by Rahul Sachdeva. The registered enrollment target is 15 participants, below the 253-participant average among 5 other Hereditary Spastic Paraplegia trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07417943, a NA study of Hereditary Spastic Paraplegia, is actively recruiting participants, sponsored by Rahul Sachdeva.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Hereditary spastic paraplegia (HSP) is a rare neurological condition that causes stiffness, weakness, and difficulty walking due to damage in the nerves that control movement. This study will test whether a noninvasive form of spinal cord stimulation, called transcutaneous spinal cord stimulation (tSCS), can improve walking and reduce muscle stiffness in adults with HSP. In this study, participants will receive tSCS twice a week for 8 weeks. The stimulation is delivered through self-adhesive electrodes placed on the skin over the lower back and does not require surgery. Each session will last about one hour. After the treatment period, participants will be followed for an additional 8 weeks without stimulation to see whether any improvements are maintained. Researchers will measure walking speed, walking endurance, muscle stiffness, and overall disease severity. Additional tests will explore changes in bladder and bowel function and muscle strength.
Primary Outcome
10MWT assesses walking speed over a 10-meter walkway at a comfortable and maximum safe pace. Timing occurs between 2 and 8 meters to exclude acceleration/deceleration, with two trials averaged per speed. Assistive devices are allowed
Conditions Studied
Interventions
- DEVICE transcutaneous spinal cord stimulation
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2028-02-01 |
| Phase | NA |
What NCT07417943 shows while recruiting
NCT07417943 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 253-participant average among 5 other Hereditary Spastic Paraplegia trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Hereditary Spastic Paraplegia appearing as the primary indexed condition, and to 1 intervention - of which transcutaneous spinal cord stimulation is the first listed.
NCT07417943 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT07417943 about?
NCT07417943 is a clinical study titled "Neuromodulation to Enhance Motor Function in HSP". Hereditary spastic paraplegia (HSP) is a rare neurological condition that causes stiffness, weakness, and difficulty walking due to damage in the nerves that control movement. This study will test whether a noninvasive form of spinal cord stimulation, called transcutaneous spinal cord stimulation (t...
What is the current status of trial NCT07417943?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2026-03-01. Estimated completion is 2028-02-01.
What conditions does trial NCT07417943 study?
This clinical trial studies the following conditions: Hereditary Spastic Paraplegia.
What interventions are being tested in trial NCT07417943?
The interventions under investigation include: transcutaneous spinal cord stimulation (DEVICE).
Who is sponsoring clinical trial NCT07417943?
This trial is sponsored by Rahul Sachdeva, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07417943 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Spastic Paraplegia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Natural History Study of Patients with HPDL Mutations
RECRUITING
-
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia
RECRUITING
-
Spastic Paraplegia - Centers of Excellence Research Network
RECRUITING
-
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
RECRUITING
-
Phenotype, Genotype and Biomarkers 2
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI